Clinical Trial Update: Safety, Tolerance, Efficacy and Pharmacokinetics of JS005 Multiple Dosing [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on JS005 evaluating safety, tolerance, efficacy, and pharmacokinetics in moderate to severe psoriasis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Plaque-type
• To Severe Psoriasis

Drugs mentioned

• JS005

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Moderate to Severe Psoriasis | Phase 1, Phase 2 | Status: COMPLETED